Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Molecular Morphology
Published in: Medical Molecular Morphology 2/2019

01-06-2019 | Original Paper

Evaluation of immunohistochemical expression of survivin and its correlation with −31G/C gene polymorphism in colorectal cancer

Authors: Zahra Heidari, Hamidreza Mahmoudzadeh Sagheb, Asiyeh Hakimi, Bita Moudi

Published in: Medical Molecular Morphology | Issue 2/2019

Login to get access

Abstract

Colorectal cancer (CRC) placed among the most common neoplasm. Survivin is a member of the inhibitor apoptosis gene family. This gene could be associated with aggressive behavior in numerous types of cancers. The aim of the present study was to evaluate the immunohistochemical expression of survivin gene and its correlation with −31G/C polymorphism in CRC patients. This case–control study was performed on 90 cases: 30 adenocarcinoma, 30 adenomatous polyp, and 30 normal colon. Immunohistochemical expression of survivin evaluated on formalin-fixed paraffin-embedded tissue and −31G/C polymorphism was analyzed by polymerase chain reaction-restriction fragment length polymorphism analysis. Results showed that the subjects carrying C/C genotype with 43.3% (p = 0.002‚ OR = 12.188, CI = 2.530–58.720) and G/C genotype with 43.3% (p = 0.032‚ OR = 4.432, CI = 1.133–17.341) significantly had increased risk of CRC compared with subjects carrying GG genotype. Allelic frequencies showed statistically significant difference (p = 0.001) among adenocarcinoma (G = 35%, C = 65%), adenomatous (G = 43.3, C = 56.7), and normal group (G = 68.3, C = 31.7). Immunohistological evaluation showed nuclear survivin protein expression in patients with the CC genotype higher than in patient with the GG and GC genotypes (p = 0.002). The results suggest that C allele of − 31G/C polymorphism in survivin might be cooperative in CRC development.
Literature
1.
2.
Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46(5):645–650CrossRefPubMedPubMedCentral
3.
Jakubowska K, Pryczynicz A, Dymicka-Piekarska V, Famulski W, Guzińska-Ustymowicz K (2016) Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients. Oncol Lett 12(5):3591–3597CrossRefPubMedPubMedCentral
4.
Mahdavinia M, Bishehsari F, Ansari R, Norouzbeigi N, Khaleghinejad A, Hormazdi M, Rakhshani N, Malekzadeh R (2005) Family history of colorectal cancer in Iran. BMC Cancer 5(1):112CrossRefPubMedPubMedCentral
5.
Rahimi Pordanjani S, Baeradeh N, Lotfi MH, Pourmohammadi B (2016) Epidemiology of colorectal cancer: incidence, mortality, survival rates and risk factors. Razi J Med Sci 23(144):41–50
6.
Dolatkhah R, Somi MH, Bonyadi MJ, Asvadi Kermani I, Farassati F, Dastgiri S (2015) Colorectal cancer in Iran: molecular epidemiology and screening strategies. J Cancer Epidemiol 2015:643020CrossRefPubMedPubMedCentral
7.
Hosseinzadeh A, Daraei A (2012) Environmental factors associated with sporadic colorectal cancer. J Health Syst Res 8:229–236
8.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96CrossRefPubMed
9.
Gayet J, Zhou X-P, Duval A, Rolland S, Hoang J-M, Cottu P, Hamelin R (2001) Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20(36):5025–5032CrossRefPubMed
10.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed
11.
Montazerhaghighi M, Najjarsadeghi R, Mohebi S, Vahedi M (2009) G1793A genotype of MTHFR gene in patients with sporadic colorectal cancer. Pejouhandeh 3:147–151
12.
Dadkhah A, Fatemi F (2010) Effects of anti tomuric property of black cumin on induced colon cancer with dimethyl hydrazine in rat. New Find Lab Res 2010:1–32
13.
Mahmoudzadeh Sagheb H, Heidari Z, Jahantigh M, Narouei M (2016) Immunohistochemical expression of p53 and Ki-67 genes in gastric cancer and precancerous lesions in the patients with Helicobacter pylori infection. Gene Cell Tissue 3(4):e41341. https://​doi.​org/​10.​17795/​gct-41341 CrossRef
14.
Liu Y, Li L, Qi H, Gao Y, Liu S, Xu C (2013) Survivin −31G>C polymorphism and gastrointestinal tract cancer risk: a meta-analysis. PLoS One 8(2):e54081CrossRefPubMedPubMedCentral
15.
Babaei E, Shariat Torbaghan S, Emadi Bayegi M (2006) Detection of survivin gene expression in formalin-fixed paraffin-embedded tissues of human osteosarcoma: its potential usefulness in diagnosis and prognosis of bone tumors. Iran Biomed J 10(1):39–45
16.
Gayathri C, Rao GV (2017) Immunohistochemical expression of Survivin in oral leukoplakia and oral squamous cell carcinoma. J Dr NTR Univ Health Sci 6(1):39
17.
Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos F-I, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP (2010) The survivin −31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Anal Cell Pathol 33(5–6):177–189CrossRef
18.
Kostić M, Nikolić N, Ilić B, Čarkić J, Milenković S, Vukadinović M (2013) Analysis of polymorphism in the survivin gene promoter as a potential risk factor for head and neck cancers development. Srp Arh Celok Lek 141(5–6):304–307CrossRefPubMed
19.
Sharief MK, Noori MA, Douglas MR, Semra YK (2002) Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis. Eur J Neurol 9(5):503–510CrossRefPubMed
20.
Shintani M, Sangawa A, Yamao N, Kamoshida S (2013) Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Exp Pathol 6(12):2919PubMedPubMedCentral
21.
Tecleab AG (2013) Regulation of the tumor suppresser p53 and survivin by Ras and Ral GTPases: implications for malignant transformation. University of South Florida, Tampa
22.
Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B (2011) Role of survivin gene promoter polymorphism (−31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol 18(3):880–887CrossRefPubMed
23.
24.
Xu L, Zhou X, Xu L, Yin R (2014) Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies. Tumor Biol 35(2):1661–1669CrossRef
25.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, Jemal A (2017) Colorectal cancer statistics, 2017. CA Cancer J Clin 67(3):177–193CrossRefPubMed
26.
27.
Sarela A, Macadam R, Farmery S, Markham A, Guillou P (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46(5):645–650CrossRefPubMedPubMedCentral
28.
Tastekin E, Caloglu VY, Durankus NK, Sut N, Turkkan G, Can N, Puyan FO, Caloglu M (2017) Survivin expression, HPV positivity and microvessel density in oropharyngeal carcinomas and relationship with survival time. Arch Med Sci 13(6):1467CrossRefPubMed
29.
Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos F-I, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP (2011) The survivin −31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol 34(4):381–391CrossRef
30.
Liu T-C, Hsieh M-J, Wu W-J, Chou Y-E, Chiang W-L, Yang S-F, Su S-C, Tsao TC-Y (2016) Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer. Int J Med Sci 13(12):929CrossRefPubMedPubMedCentral
31.
Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, Mirmiran A, Khorsandi M-T, Larijani B, Mostaan LV (2012) Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 208(2):100–103CrossRefPubMed
32.
Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, Mahrampour E, Larijani B, Tavakkoly-Bazzaz J, Amoli MM (2012) Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer 22(1):35–37CrossRefPubMed
33.
34.
Bogdanovic L, Lazic M, Bogdanovic J, Soldatovic I, Nikolic N, Radunovic M, Radojevic-Skodric S, Milasin J, Basta-Jovanovic G (2017) Polymorphisms of survivin −31 G/C gene are associated with risk of urothelial carcinoma in Serbian population. J BU ON 22(1):270
35.
Hossein Pour Feizi M, Rojhan Nejad M, Pouladi N, Azarfam P, Montazeri V, Halimi M (2012) The study of survivin gene promoter polymorphism (−31G/C) in breast cancer in north west of Iran. SSU J 20(4):420–428
36.
Yamak N, Yaykasli KO, Yilmaz U, Eroz R, Uzunlar AK, Ankarali H, Sahiner C, Baltaci D (2014) Association between survivin gene polymorphisms and the susceptibility to colon cancer development in the Turkish population. Asian Pac J Cancer Prev 15(20):8963–8967CrossRefPubMed
37.
Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, Satoh S, Mitobe Y, Narita S, Habuchi T (2011) Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer 129(8):1872–1880CrossRefPubMed
38.
Negi A, Puri A, Gupta R, Nangia R, Sachdeva A, Mittal M (2015) Comparison of immunohistochemical expression of antiapoptotic protein survivin in normal oral mucosa, oral leukoplakia, and oral squamous cell carcinoma. Pathol Res Int 2015:1–6CrossRef
39.
Abdelrahman AE, Abdel-Aziz HR, Hegazy AA, Mohamed A-M (2016) Immunohistochemical study of prognostic relevance of nestin and survivin expression in astrocytic glioma. J Interdiscip Histopathol 4(2):34–40CrossRef
40.
Li Y, Zhou Y, Zheng J, Niu C, Liu B, Wang M, Fang H, Hou C (2015) Downregulation of survivin inhibits proliferation and migration of human gastric carcinoma cells. Int J Clin Exp Pathol 8(2):1731PubMedPubMedCentral
Metadata
Title
Evaluation of immunohistochemical expression of survivin and its correlation with −31G/C gene polymorphism in colorectal cancer
Authors
Zahra Heidari
Hamidreza Mahmoudzadeh Sagheb
Asiyeh Hakimi
Bita Moudi
Publication date
01-06-2019
Publisher
Springer Japan
Published in
Medical Molecular Morphology / Issue 2/2019
Print ISSN: 1860-1480
Electronic ISSN: 1860-1499
DOI
https://doi.org/10.1007/s00795-018-0204-0

Other articles of this Issue 2/2019

Medical Molecular Morphology 2/2019 Go to the issue

Original Paper

Enhanced expression of nidogen 1 around the nest of basal cell carcinoma compared with that around squamous cell carcinoma

Original Paper

Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Original Paper

Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer

Original Paper

Knockdown of long non-coding RNA PCAT1 in glioma stem cells promotes radiation sensitivity

Original Paper

FGF-2 combined with bilayer artificial dermis composed of collagen matrix prompts generation of fat pad in subcutis of mice

Review

Protective role of heme oxygenase-1 in fatty liver ischemia–reperfusion injury